Navidea and Norgine Enter European Commercial Partnership for Lymphoseek®; Navidea to Receive $2 Million Upfront Payment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Navidea Biopharma (NAVB) Reports In-Line Q4 EPS
March 5, 2015 7:31 AM ESTNavidea Biopharma (NYSE: NAVB) reported Q4 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $2.2 million versus the consensus estimate of $2.1 million.
For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.
... MoreNavidea Biopharma (NAVB), SpePharm AG Emter Distribution Agreement for Lymphoseek in EU
March 5, 2015 7:16 AM ESTNavidea Biopharma (AMEX: NAVB) and SpePharm AG (an affiliate of Norgine BV), a European specialist pharmaceutical company with an extensive pan-European presence, entered into an exclusive sublicense agreement for the commercialization and distribution of Lymphoseek® 250 microgram kit for radiopharmaceutical preparation (tilmanocept) in the European Union. Under the terms of the agreement, Navidea will receive an upfront payment of $2 million and is eligible to receive additional milestone payments up to $5 million, as well as royalties on European net sales.
Lymphoseek is a receptor-targeted, radiopharmaceutical imaging agent approved by the U.S. Food... More
